2 terminated, 1 active not recruiting. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 2, Active not recruiting 1 |
| Phase 2 | 3 | Terminated 2, Active not recruiting 1 |
Follow Mesothelioma Peritoneum: new trials by email Literature Review of Mesothelioma Peritoneum trials Research Report on Mesothelioma Peritoneum
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral AMXT 1501 Dicaprate in Combination With IV DFMO AMXT1501, DFMO - Cancer, Solid Tumor | Phase 1 / Phase 2 | Terminated | Aminex Therapeutics, Inc. | 15 | 2022-11-29 | 2024-12-24 |
| A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer TC-510, Fludarabine, Cyclophosphamide - Mesothelioma, Mesotheliomas Pleural | Phase 1 / Phase 2 | Terminated | TCR2 Therapeutics | 14 | 2022-06-21 | 2026-07-13 |
| Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer gavo-cel, fludarabine, cyclophosphamide - Mesothelioma, Mesothelioma, Malignant | Phase 1 / Phase 2 | Active not recruiting | TCR2 Therapeutics | 57 | 2019-04-15 | 2025-08-27 |
Carcinoma, Non-Small-Cell Lung (3) · Mesothelioma, Malignant (3) · Ovarian Neoplasms (3) · Cholangiocarcinoma (2) · Colorectal Neoplasms (2) · Mesothelioma (2) · Breast Neoplasms (1) · Diffuse Intrinsic Pontine Glioma (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Glioma (1) · Head and Neck Neoplasms (1) · Melanoma (1) · Neoplasms (1) · Pancreatic Neoplasms (1)
Adenocarcinoma (3) · Adenoma (3) · Adnexal Diseases (3) · Bronchial Neoplasms (3) · Carcinoma (3) · Carcinoma, Bronchogenic (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genital Diseases (3) · Genital Diseases, Female (3) · Genital Neoplasms, Female (3) · Gonadal Disorders (3) · Lung Diseases (3)
Cyclophosphamide (2) · fludarabine (2) · Ipilimumab (1) · Nivolumab (1)
TCR2 Therapeutics (2) · Aminex Therapeutics, Inc. (1)
United States (3) · Australia (1) · Canada (1)
Michael Armstrong, MD (1) · Sue Lee, MD (1)